AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise (CM...

Courtesy MedPage Today Infectious Disease  Tue, 11/03/2009 - 10:26

BOSTON (MedPage Today) -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, in contrast with the three-times-per-day schedule needed for similar drugs in development.

Tags:

 

More related items

ASN: HCV Infection Virtually Untreated in Dialysis...
PHILADELPHIA (MedPage Today) -- Hepatitis C virus (HCV) infection is associated with an increase in mortality in patients on hemodialysis, but treatment is rare in that population,...

Drug Ups Response Rate in Refractory Hepatitis C...
(MedPage Today) -- The protease inhibitor, telaprevir (Incivek), markedly improved response rates in patients with hard-to-treat hepatitis C virus (HCV) infection, compared with standard...

DDW: Study Backs HCV Screens for All Boomers (CME/CE)
CHICAGO (MedPage Today) -- Screening all baby boomers for hepatitis C virus (HCV) infection could save tens of thousands of lives at a very acceptable cost, a researcher said here.

Country Save HE Laundry Detergent, Powder, 160-Load,...

Yogi Tea Calm, Bedtime, Tea Bags, 16-Count Boxes...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com